ImmuPharma (LSE:IMM), the drug discovery and development company behind the lupus candidate P140, published interim results on 15 September 2026 covering the six months to 30 June 2026. The figures showed a modestly lower operating loss but a larger reported loss driven by an accounting remeasurement, while management reiterated its aim of securing a commercial deal for P140 during 2026.

What the Company Does

ImmuPharma is an AIM-quoted specialist biopharmaceutical business. Its lead asset is P140, also known as Lupuzor or forigerimod, which it is developing as a treatment for autoimmune disease, notably lupus. The company is also developing Kapiglucagon, a proprietary glucagon prodrug aimed mainly at dual-hormone artificial pancreas systems, as well as preclinical anti-infective programmes called BioAMB and BioCIN, targeting fungal and bacterial infections respectively. Tim McCarthy serves as chief executive and chairman.

Latest Developments

In the interim statement, ImmuPharma said it received its first UK Combined Search and Examination Report on P140 in March 2026 and filed an international Patent application after the period end. The company is pursuing a precision medicine approach, which it calls Type M, designed to identify patients most likely to respond to treatment.

Discussions with Avion Pharmaceuticals, its US licensing partner for P140, were described as constructive, with the company aiming to secure a commercial deal in 2026. No such agreement had been announced at the time of the interim results.

For Kapiglucagon, the company said the development plan has been approved, specialist partners have been selected and preparations are under way for interaction with the US Food and Drug Administration to inform the programme ahead of investigational new drug enabling work.

Financial Picture

The operating loss for the half was £1.1 million, slightly below the £1.2 million recorded a year earlier. The reported loss, however, widened to £4.7 million from £1.9 million, largely reflecting a £3.36 million finance loss from remeasuring a derivative financial asset at fair value. The company noted that this line moves with its share price and can generate gains as well as losses. Cash stood at £0.7 million at 30 June 2026, up from £0.4 million a year earlier. As a development-stage business, ImmuPharma does not pay a dividend.

Funding

In April 2026, ImmuPharma completed a fundraising with gross proceeds of about £6.47 million. This comprised a £6.0 million subscription by Lanstead Capital Investors and around £0.47 million from a retail offer. The Lanstead money is linked to a 20-month sharing agreement, meaning the final cash received depends on how the share price performs against a benchmark. The directors said the funding, together with existing cash, is expected to provide a runway into at least the second half of 2028.

Sector and index Context

ImmuPharma is one of many early-stage life sciences names on the FTSE AIM All Share Index, a group where value often hinges on clinical progress, partnering news and access to capital. Biotech sentiment on AIM can be volatile, and licensing agreements are frequently a key catalyst for smaller developers.

Key Risks

The structure of the Lanstead arrangement exposes the company's funding to share price movements, and the derivative remeasurement can create sizeable swings in reported results. P140 has a long development history, and there is no guarantee that a commercial deal will be agreed or that regulators will accept the planned approach. Kapiglucagon and the anti-infective programmes remain at an early stage.

What to Watch Next

Investors will watch for any announcement on a P140 commercial agreement with Avion, progress on regulatory engagement for Kapiglucagon and updates on patent applications. Share price performance against the sharing agreement benchmark will also influence the company's cash position.